Strategies Employed for the Development of PARP Inhibitors

Canan, S; Maegley, K; Curtin, NJ

doi:10.1007/978-1-4939-6993-7_18

Strategies Employed for the Development of PARP Inhibitors

Lookup NU author(s): Professor Nicola Curtin ORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2017, Springer Science+Business Media LLC. This chapter describes the approaches taken in the development of the first PARP inhibitor to enter clinical trial, rucaparib (now called Rubraca), in 2003. We describe the general principles of crystal-based drug design, the purification and crystallization of the PARP-1 catalytic domain and how this was used to develop highly potent PARP inhibitors, based on the nicotinamide pharmacophore. Several methods have been used to determine the inhibitory potency in cell-free and whole cell assays, each described with reference to its advantages and disadvantages.